Isolagen, Inc. Reports Results of Shareholders Annual Meeting
EXTON, Pa., Nov. 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. today announced the results of its 2007 Annual Meeting of Stockholders, held today in Exton, Pennsylvania.
Stockholders elected Dr. Kenneth A. Selzer to serve as a new Director. Dr. Selzer has been a partner with the venture capital firm of Finistere Ventures. Concurrently, since 2005, Dr. Selzer has been executive director of the Hallowell-West Medical Center, which specializes in the diagnosis and treatment of patients with Attention Deficient Disorders (ADD/ADHD) and associated learning disorders. From 2002 until 2005, Dr. Selzer was a general partner with Neuropractice Consulting Group, which provides specialized services for companies investing in drugs, biologics and medical devices. Dr. Selzer is currently on the Board of Directors of INC Research, a global clinical research organization (CRO) and a company which he founded in 1996. Dr. Selzer is a graduate of both the UCLA School of Medicine and the OPM executive management program at Harvard Business School and is a Diplomat of both the American Board of Neurology and the American Board of Pain Medicine.
"We are pleased to welcome Dr. Selzer to our Board of Directors," said Nicholas L. Teti, Chairman and CEO of Isolagen Inc. "Ken brings a wealth of clinical, medical and business knowledge to Isolagen and we look forward to benefiting from his broad experience."
Stockholders also re-elected Steven Morrell, Partner, Teknoinvest AS, and Marshall G. Webb, President of Polaris Group, as Directors.
The terms of these three Directors will run through the 2010 Annual Meeting of Stockholders.
Further, the Company's stockholders ratified the appointment of BDO Seidman, LLP as the Company's auditors for the year ending December 31, 2007.
About Isolagen, Inc.
Isolagen(TM), Inc. is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit www.isolagen.com.
Isolagen Forward Looking Statements
All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.
CONTACT: Media, Mike Beyer, Sam Brown Inc., +1-773-463-4211,
beyer@sambrown.com, for Isolagen; Investors, Charles Huiner, Isolagen,
+1-484-713-6200, chuiner@isolagen.com
Web site: http://www.isolagen.com/